第二季度净收入7.2亿-7.3亿美元，同比增长约3%; EBITDA 1.8亿-1.85亿美元，同比增长约13%

– Results Reflect Continued Financial Strength and Deleveraging –

BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced certain unaudited preliminary financial results for the second quarter ended June 30, 2025. The Company plans to report actual second quarter 2025 financial results on August 5, 2025.

Unaudited Preliminary Financial Results for the Second Quarter Ended June 30, 2025

• Net revenue of $720 million to $730 million, an increase of approximately 3% versus the same period in 2024
   
• Income before income taxes of $45 million to $56 million, versus $20 million in the same period in 2024
   
• Adjusted EBITDA of $180 million to $185 million, an increase of approximately 13% versus the same period in 2024
   
• Gross leverage decreased to 3.8x as of June 30, 2025, compared to 4.1x as of December 31, 2024, and net leverage decreased to 3.7x as of June 30, 2025, compared to 3.9x as of December 31, 2024, due to higher profitability and continued debt reduction